DiaMedica Therapeutics Inc. DMAC R2K
Healthcare · Biotechnology · United States
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
READ MORE ›$5.99
+45.74% 1Y
Market & Price
Market Cap
$322.76M
Current Price
$5.99
High / Low (52W)
$9.39 / $3.51
Beta
0.99
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.88
Price to Book
6.83
P/S
-
EV/EBITDA
-7.40
Dividend Yield
-
Profitability & Returns
ROCE
-61.16%
ROE
-86.47%
ROA
-49.96%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.19
EPS (TTM)
$-0.71
Balance Sheet & Liquidity
Debt/Equity
0.45
Quick Ratio
8.98
Current Ratio
9.11
Debt
$212.00K
Total Assets
$61.37M
Current Assets
$60.63M
Working Capital
$55.50M
Ownership
Promoter Holding
27.74%
Chg in Prom Hold
-
FII / Inst Holding
37.77%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$271.64M
Total Revenue (TTM)
-
EBITDA
$-36.69M
Free Cash Flow
$-18.01M
Operating Cash Flow
$-31.00M
Shares Outstanding
53.88M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-46.53%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -46.5% CAGR over 5 years.
- Trading 36.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DMAC DiaMedica Therapeutics Inc. R2K | 5.99 | - | $322.76M | - | -61.16% | -86.47% | - | -46.53% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 500.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.14M | 8.01M | 9.03M | 9.21M | 10.48M |
| Operating Income | -1.31M | -1.85M | -1.49M | -3.42M | -2.74M | -2.66M | -2.40M | -2.71M | -3.32M | -3.62M | -3.37M | -3.42M | -3.54M | -3.36M | -3.13M | -5.52M | -4.74M | -5.16M | -5.74M | -5.64M | - | -8.14M | -8.01M | -9.03M | -9.21M | -10.48M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.13M | -8.00M | -9.02M | -9.20M | -10.47M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.70M | -7.69M | -8.61M | -8.73M | -10.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.00K | 6.00K | 6.00K | 10.00K | 7.00K |
| Net Income | -650.00K | -1.74M | -1.39M | -3.25M | -2.47M | -2.45M | -2.42M | -2.47M | -3.19M | -3.62M | -3.27M | -3.45M | -3.51M | -3.36M | -3.06M | -5.27M | -4.48M | -4.47M | -5.15M | -5.12M | - | -7.71M | -7.70M | -8.62M | -8.74M | -10.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.15 | -0.18 | -0.18 | -0.17 | - | -0.19 |
| R&D Expense | 791.00K | 1.07M | 1.21M | 2.61M | 1.87M | 1.62M | 1.35M | 1.60M | 2.16M | 2.41M | 2.16M | 2.33M | 1.97M | 1.96M | 1.64M | 3.62M | 2.54M | 3.27M | 3.68M | 3.93M | 4.98M | 5.66M | 5.82M | 6.44M | - | 7.99M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 500.00K | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 14.00M | 21.27M | 26.68M | 34.40M |
| Operating Income | -4.52M | -6.76M | -11.59M | -12.70M | -13.65M | -14.00M | -21.27M | -26.68M | -34.40M |
| EBITDA | - | - | - | - | - | -13.98M | -21.24M | -26.64M | -34.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -13.65M | -19.34M | -24.41M | -32.74M |
| Tax Provision | - | - | - | - | - | 28.00K | 43.00K | 30.00K | 28.00K |
| Net Income | -4.26M | -5.73M | -10.65M | -12.29M | -13.59M | -13.68M | -19.38M | -24.44M | -32.77M |
| Diluted EPS | - | - | - | - | - | -0.52 | -0.60 | -0.60 | -0.70 |
| R&D Expense | 3.21M | 4.52M | 7.90M | 8.21M | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -46.53% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +45.74% |
| 6 Months: | -33.67% |
| 3 Months: | -24.65% |
| 1 Month: | +0.50% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.80M | 18.34M | 9.05M | 28.09M | - | 34.40M | 54.16M | 46.34M | 61.37M |
| Current Assets | - | - | - | - | - | - | 33.84M | 53.67M | 44.61M | 60.63M |
| Cash & Equivalents | - | 1.35M | 16.82M | 3.88M | 7.41M | - | 4.73M | 4.54M | 3.02M | 15.65M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 2.00K | 71.00K | 1.00K | 8.00K |
| Total Liabilities | - | - | - | - | - | - | 2.57M | 3.10M | 5.63M | 5.26M |
| Current Liabilities | - | 1.00M | 1.30M | 1.32M | 2.03M | - | 2.17M | 2.79M | 5.39M | 5.13M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 469.00K | 400.00K | 340.00K | 240.00K |
| Total Equity | 1.11M | 799.00K | 17.02M | 7.62M | 26.01M | - | 31.83M | 51.06M | 40.72M | 56.11M |
| Shares Outstanding | - | - | - | - | - | - | 26.44M | 37.96M | 42.82M | 53.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.90M | -5.70M | -9.10M | -9.19M | - | -11.51M | -18.73M | -22.08M | -29.06M |
| Investing Cash Flow | -22.00K | -50.00K | -3.91M | -16.13M | - | 11.54M | -18.30M | 8.56M | -2.19M |
| Financing Cash Flow | 3.54M | 21.22M | 70.00K | 28.84M | - | -6.00K | 36.84M | 11.99M | 43.88M |
| Capital Expenditure | -22.00K | -50.00K | -2.00K | -47.00K | - | -81.00K | -24.00K | -25.00K | -40.00K |
| Free Cash Flow | -3.92M | -5.75M | -9.10M | -9.23M | - | -11.59M | -18.75M | -22.10M | -29.10M |
| Net Change in Cash | - | - | - | - | - | 21.00K | -185.00K | -1.52M | 12.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -1,352.2% | - | - | - | - | - | - | - |
| Net Margin % | - | -1,146.8% | - | - | - | - | - | - | - |
| ROE % | -533.2% | -33.7% | -139.8% | -47.3% | - | -43.0% | -38.0% | -60.0% | -58.4% |
| ROCE % | -565.6% | -39.7% | -149.9% | -48.7% | - | -43.4% | -41.4% | -65.1% | -61.2% |
Shareholding Pattern
Insiders
27.74%
Institutions
37.77%
Public Float
52.27%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cooperman, Leon G. | 3.75% | 2.02M | $12.10M |
| 2 | Blackrock Inc. | 3.44% | 1.86M | $11.12M |
| 3 | Millennium Management Llc | 1.74% | 935.59K | $5.60M |
| 4 | Paragon Associates & Paragon Associates Ii Joint Venture | 1.62% | 875.00K | $5.24M |
| 5 | Geode Capital Management, LLC | 1.45% | 780.52K | $4.68M |
| 6 | State Street Corporation | 1.20% | 644.21K | $3.86M |
| 7 | First Manhattan Co. LLC | 0.84% | 455.00K | $2.73M |
| 8 | Bleichroeder LP | 0.71% | 382.32K | $2.29M |
| 9 | Northern Trust Corporation | 0.63% | 338.53K | $2.03M |
| 10 | Vanguard Capital Management LLC | 0.62% | 333.46K | $2.00M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMAC
No recent headlines available.